clinical trial

[Genprex, Inc.] Genprex, Inc. announced that the FDA has granted Fast Track Designation for the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Merck & Co’s Keytruda® in patients with histologically-confirmed unresectable stage III or IV non-small cell lung cancer whose disease progressed after treatment with Keytruda.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators demonstrated that teprotumumab, an anti-insulin-like growth factor I receptor inhibitor, attenuated constitutive expression and induction by the thyroid-stimulating hormone of MHC II and these B7 members in CD34+ fibrocytes.

[Tissue Engineering and Regenerative Medicine] Researchers reported a novel strategy to generate highly pure mouse bone marrow MSCs using liposomal clodronate.

[Antios Therapeutics, Inc.] Antios Therapeutics, Inc. and Arbutus Biopharma Corporation announced that the first patient has been dosed in a triple combination treatment in patients with chronic hepatitis B virus infection.

[Molecular Psychiatry] Scientists focus on cerebral dopamine neurotrophic factor (CDNF), an unconventional neurotrophic protein. CDNF delivered to the brain parenchyma protects and restores dopamine neurons in animal models of Parkinson’s disease.

[CoImmune, Inc.] CoImmune, Inc. announced that results from a Phase I/II clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company’s chimeric antigen receptor modified cytokine induced killer cell platform, demonstrated sustained responses in pediatric and adult patients with B-cell acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic stem cell transplantation.